Press releases
Read more:
Categories
2019
English translation NIC-001 is Nanologica’s sublingual formulation of metoclopramide for treating gastroparesis patients. The process for preparing...
After regulatory investigations and an extended market analysis, Nanologica advances the project NIC-001 towards clinical phase IIa. The market analysis...
2019-08-20 12:39
Start of large-scale production of silica
Large-scale production of Nanologica’s silica has now started at the contract manufacturer Sterling Pharma Solutions Ltd. in Newcastle, United Kingdom...
2019-07-02 12:33
Nanologica starts business within preparative chromatography with profitable agreement
Nanologica enters into an agreement with Chinese Yunbo Technology (Beijing) Co. for the delivery of preparative chromatography media to a value of approximately...
2019-04-30 12:16
Nanologica's patent issued in the USA
Nanologica announces that the United States Patent and Trademark Office has issued Nanologica’s patent titled ”Improved method for stem cell...
2019-03-08 12:09
Nanologica to attend BIO-Europe 2019, Mar 25-27 in Vienne for partnering Discussions
Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25 – 27 to meet with potential pharmaceutical partners regarding co-development...
2019-01-30 12:02
Nanologica and AstraZeneca joint evaluation project
Nanologica and AstraZeneca have entered into an agreement for the evaluation of Nanologica’s pending patented technology, applied to AstraZeneca...
2018
2018-11-08 11:40
Nanologica expands its technology platform
One of Nanologica’s patent applications has today become public. Through the patent, Nanologica is seeking to strengthen and expand its technology...
2018-10-03 11:36
Exclusivity agreement for the Chinese market
Nanologica AB (publ) has today entered into a five-year distribution agreement with Yunbo Technology (Beijing) Co. for the Chinese market. The agreement...
2018-07-03 11:24
Nanologica one step closer to milestone payment
Vicore Pharma AB (publ) will decide on an acquisition of INIM Pharma AB, where Nanologica AB is a minor shareholder, in an Extraordinary General Meeting...